We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Tolerability, Efficacy, and Safety of Pegylated Liposomal Doxorubicin in Combination with Carboplatin Versus Gemcitabine-Carboplatin for the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer: A Systematic Review.
- Authors
Holloway, Robert W.; Grendys, Edward C.; Lefebvre, Patrick; Vekeman, Francis; McMeekin, Scott
- Abstract
Objective. To compare the tolerability, efficacy, and safety profiles of pegylated liposomal doxorubicin in combination with carboplatin (PLD-Carbo) with those of gemcitabine-carboplatin (Gem-Carbo) for the treatment of patients with platinum-sensitive recurrent ovarian cancer (PSROC) by reviewing the published literature. Methods. Using the PubMed database, a systematic review of peer-reviewed literature published between January 2000 and September 2009 was undertaken to identify studies related to the treatment of patients with PSROC with PLD-Carbo or Gem-Carbo. Studies reporting either response rate, progression-free survival (PFS), and/or overall survival (OS) were included. Treatment regimens, efficacy endpoints, and safety profiles were compared between the two combination therapies. Results. Ten studies evaluating 608 patients (PLD-Carbo: 5 studies, 278 patients; Gem-Carbo: 5 studies, 330 patients) were identified. The mean planned doses were: PLD, 34.8 mg/m2 and Gem, 993 mg/m2. The dose intensity reported in Gem trials was lower (75% of the planned dose) than the dose intensity reported in PLD trials (93.7% of the planned dose), suggesting better tolerability for the PLD-Carbo regimen. Among patients receiving PLD-Carbo, 60.2% achieved a response (complete, 27.0%; partial, 33.2%), versus 51.4% of patients treated with Gem-Carbo (complete, 19.2%; partial, 32.2%). The median PFS times were 10.6 months and 8.9 months in the PLD-Carbo and the Gem-Carbo populations, respectively. The median OS was longer for the PLD-Carbo regimen (27.1 months) than for the Gem-Carbo regimen (19.7 months).
- Subjects
ANTINEOPLASTIC agents; CANCER relapse; DOXORUBICIN; DRUG delivery systems; MEDLINE; ONLINE information services; HEALTH outcome assessment; OVARIAN tumors; RESEARCH funding; SYSTEMATIC reviews; EVIDENCE-based medicine; DRUG administration; DRUG dosage; DRUG therapy
- Publication
Oncologist, 2010, Vol 15, Issue 10, p1073
- ISSN
1083-7159
- Publication type
Article
- DOI
10.1634/theoncologist.2009-0331